Abstract
In mutagenicity testing of pharmaceuticals it is advisable, whenever possible, to use in vivo mammalian systems where the pharmacokinetic properties of a drug would be more or less similar to those in man. However, although there are a number of different genetic endpoints which are important in mutagen testing, sufficiently validated, practical and well documented in vivo test systems exist only for stuctural chromosome aberrations.
This paper provides an overview of existing in vivo test systems for the detection of chromosome aberrations. Emphasis has been laid on the functions, advantages and limitations of the three tests recommended in the guidelines of the European Community; first, the metaphase analysis assay, and, as alternatives, the micronucleus test and the dominant lethal test.
These three test are then also discussed from the viewpoint of our own practical experience.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen JW, Skuller CF, Mendes RW, Latt SA (1977) A simplified technique for in vivo analysis of sister chromatid exchanges using 5-bromodeoxy ridine tablets. Cytogenet Cell Genet 18:231–237
Bateman AJ (1977) The dominant lethal assay in the male mouse. In: Kilbey B, Legator M, Nichols W, Ramel C (eds) Handbook of mutagenicity test procedures. Elsevier, Amsterdam New York Oxford, p 243
Bateman AJ, Epstein SS (1971) Dominant lethal mutations in mammals. In: Hollaender A (ed) Chemical mutagens, vol 2. Plenum Press, New York London, p 541
Binkert F, Schmid W (1977) Pre-implantation embryos of Chinese hamster. Mutat Res 46:62–86
Brewen JG, Preston RJ (1978) Analysis of chromosome aberrations in mammalian germ cells. In: Hollaender A (ed) Chemical mutagens, vol 5. Plenum Press, New York London, p 127
Cohen MM, Hirschhorn K (1971) Cytogenetic studies in animals. In: Hollaender A (ed) Chemical mutagens, vol 2. Plenum Press, New York London, p 515
EEMS-Report (1978) Mutagenicity Screening: General principles and minimal criteria. Mutat Res 53:361–370
Evans HJ (1976) Cytological methods for detecting chemical mutagens. In: Hollaender A (ed) Chemical mutagens, vol 4. Plenum Press, New York London, p 1
Evans HJ, D'Riordan ML (1977) Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. In: Kilbey BJ, Legator M, Nichols W, Ramel C (eds) Handbook of mutagenicity test procedures. Elsevier, Amsterdam New York Oxford, p 261
Generoso WM, Cain KT, Huff SW, Gosslee DG (1978) Heritable translocation test in mice. In: Hollaender A (ed) Chemical mutagens, vol 5. Plenum Press, New York London, p 55
Kilian DJ, Moreland FM, Benge MC, Legator MS, Whorton EB (1977) A collaborative study to measure interlaboratory variation with the in vivo bone marrow metaphase procedure. In: Kilbey BJ, Legator M, Nichols W, Ramel C (eds) Handbook of mutagenicity test procedure. Elsevier, Amsterdam New York Oxford, p 243
Latt SA, Allen JW, Rogers WE, Juergens LA (1977) In vitro and in vivo analysis of sister chromatid exchange formation. In: Kilbey BJ, Legator M, Nichols W, Ramel C (eds) Handbook of mutagenicity test procedures. Elsevier, Amsterdam New York Oxford, p 275
Léonard A (1973) Observations on meiotic chromosomes of the male mouse as a test of the potential mutagenicity of chemicals in mammals. In: Hollaender A (ed) Chemical mutagens, vol 3. Plenum Press, New York London, p 21
Matter BE (1976a) Problems of testing drugs for potential mutagenicity. Mutat Res 38:243–258
Matter BE (1980) Mutagenicity screening of new drugs. In: Alacevic M (ed) Progress in Environmental Mutagenesis. Elsevier/North-Holland, Amsterdam, p 191
Matter BE, Grauwiler J (1974) Micronuclei in bone marrow cells. Mutat Res 23:239–249
Matter BE, Jaeger I (1976) Premature chromosome condensation, structural chromosome aberrations, and micronuclei in early mouse embryos. Mutat Res 33:251–260
Matter BE, Tsuchimoto T, Deyssenroth H (1978) Failure to detect dominant lethal mutations and effects on reproductive capacity in mice exposed to dihydro-ergotoxine mesylate. Drug Res 28:2286–2290
Notes for Guidance on the Testing of Medicinal Products for Their Mutagenic Potential (1979) Draft Guidelines, European Community, Brussels
Röhrborn G, Hausmann I, Buckel U (1977) Cytogenetic analysis of pre- and postovulatory ocytes and pre-implantation embryos in mutagenesis of mammals. In: Kilbey BJ, Legator M, Nichols W, Ramel C (eds) Handbook of mutagenicity test procedures. Elsevier, Amsterdam New York Oxford, p 301
Russel LB (1976) Numerical sex-chromosome anomalies in mammals. Their spontaneous occurrence and use in mutagenesis studies. In: Hollaender A (ed) Chemical mutagens, vol 4. Plenum Press, New York London, p 55
Schmid W (1976) The micronucleus test for cytogenetic analysis. In: Hollaender A (ed) Chemical mutagens, vol 4. Plenum Press, New York London, p 31
Schmid W (1977) The micronucleus test. In: Kilbey BJ, Legator M, Nichols W, Ramel C (eds) Handbook of mutagenicity test procedures. Elsevier, Amsterdam New York Oxford, p 235
Staub JE, Matter BE (1976) Heritable reciprocal translocations and sperm abnormalities in the F1-offspring of male mice treated with TEM. Arch Genet 49/50:29–41
Tsuchimoto T, Stalder GR (1976) Effects of an ergot derivative on human lymphocyte chromosomes in vivo. Drug Res 26:2101–2103
Tsuchimoto T, Matter BE (1979) In vivo cytogenetic screening methods for mutagens, with special reference to the micronucleus test. Arch Toxicol 42:239–248
Author information
Authors and Affiliations
Additional information
Chemical Substances Mentioned: Trisethylenemelamine (TEM), Trenimon, Cyclophosphamide, Mitomycin C, Colchicine, Benzimidazol carbamate, Azathioprine
Rights and permissions
About this article
Cite this article
Matter, B.E., Tsuchimoto, T. Mutagenicity test systems for the detection of chromosome aberrations in vivo. Arch. Toxicol. 46, 89–98 (1980). https://doi.org/10.1007/BF00361248
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00361248